A NEW LEVEL OF SUPPLY CHAIN SECURITY FROM MASS DIGITALISATION OF MEDICINES
Colorcon's Kelly Boyer, PwC's Trent Lund and TruTag's Barry McDough describe a means of mass digitalising medicines to address the problem of illegal and unauthorised production of pharmaceutical products in a meaningful way.
Fred Metzmann reports on the latest state-of-the-art developments in innovative injection devices for combination products in subcutaneous self-application. He outlines Haselmeier's product platform strategy for single-use (D-Flex) and re-usable (i-pen²) injection-pen systems, and related services and looks at the company’s connected digital solutions.
Napoleon Monroe asks why connectivity has failed to advance rapidly, and argues that many stakeholders can benefit if the adoption of connectivity for drug delivery can be accelerated. While this article will centre on pharmaceutical combination products, the essential points also relate more broadly to pharmaceuticals and medical devices.
David Fink and Stefan Gaul use the example of Haselmeier’s D-Flex system to explain why it is important to undertake a full use-related risk analysis for injection pen products to assess their usability and identify any risks, highlighting the importance of considering usability right from the start.
In the context of the growing shift in emphasis from improving adherence to the better outcomes that can arise from doing so, Iain Simpson discusses why connectivity is becoming increasingly important in injectable drug delivery, and how it can benefit patients, providers and pharmaceutical manufacturers.